Purine-metabolizing enzymes and nucleic acid synthesis machinery

The purine-metabolizing enzymes and nucleic acid synthesis machinery represent a collective group of enzymes responsible for the production, interconversion, and degradation of purine nucleotides, which are vital components of DNA, RNA, and energy carriers like ATP (StatPearls, 2023). This metabolic network includes the de novo synthesis pathway, which builds nucleotides from simple precursors, and the salvage pathway, which recycles free bases (NIH, 2022). Because rapidly proliferating cells, such as malignant cells and activated lymphocytes, are highly dependent on these pathways for genomic replication, they are primary targets for chemotherapy and immunosuppression (PubMed, 2021). Drugs like methotrexate, 6-mercaptopurine, and mycophenolate mofetil exert their effects by inhibiting specific enzymes like dihydrofolate reductase or inosine monophosphate dehydrogenase, thereby halting the cell cycle (PubChem, 2023). Additionally, enzymes like xanthine oxidase are targeted by drugs such as allopurinol to prevent the accumulation of uric acid, the end product of purine catabolism, in conditions like gout (Wikipedia, 2024). Therapeutic intervention in these pathways requires careful monitoring due to the potential for systemic toxicities, particularly in tissues with high turnover rates like the bone marrow and intestinal epithelium (StatPearls, 2023). Genetic variations in enzymes like thiopurine S-methyltransferase (TPMT) can significantly influence drug metabolism and safety, necessitating personalized dosing strategies (PubMed, 2021).

Other names

Purine metabolic pathwayPurine biosynthetic machineryNucleotide synthesis pathwayPurine metabolism

Inhibition of de novo purine biosynthesis, inhibition of the purine salvage pathway, and competitive inhibition of enzymes required for DNA and RNA polymerisation.